MedTrace Logo

Early Use of Hyperimmune Plasma in COVID-19

NCT04721236 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 260

Last updated 2022-03-31

No results posted yet for this study

Summary

The study assesses the efficacy of early administration of hyperimmune plasma in covid-19 patients who are on CPAP or intubated. Efficacy is measured as a 2 point decrease in the WHO scale

Conditions

  • Covid19

Interventions

OTHER

hyperimmune plasma

plasma collected from convalescent Covid-19 donors with titre 1:80 or more

Sponsors & Collaborators

  • Fondazione IRCCS Policlinico San Matteo di Pavia

    collaborator OTHER

  • Catherine Klersy

    lead OTHER

Principal Investigators

  • Francesco Mojoli, MD · Fondazione IRCCS Policlinico San Matteo

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-19
Primary Completion
2021-05-19
Completion
2022-05-19

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04721236 on ClinicalTrials.gov